Variant-Resistant Antibody Recognition from a Global Consortium

Explore a 26-minute webinar presented by Dr. Erica Ollmann Saphire, President, CEO, and Professor at the La Jolla Institute for Immunology, on variant-resistant antibody recognition from a global consortium. Gain insights into the Coronavirus Immunotherapeutic Consortium (CoVIC), an international effort comparing therapeutic antibody candidates against the SARS-CoV-2 spike protein. Learn about the blinding process, multiple partner reference labs, and various analyses conducted, including in vivo protection, affinity for spike protein, epitope binning, ACE-2 binding blockage, neutralization studies, mutagenic escape risk assessment, and Fc-mediated immune effector function. Discover how this unique opportunity compiles information from diverse antibody sources, including COVID-19 survivors and in silico designs, to inform the development of potent, escape-resistant antibody therapies.

Variant-Resistant Antibody Recognition from a Global Consortium